Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report

Autor: Laura Boswell, Gregori Casals, Jesús Blanco, Amanda Jiménez, Francisco Aya, Ana deHollanda, Irene Halperin, Ana M Arance, Mireia Mora, Felicia A Hanzu

Publikováno v: Journal of Diabetes Investigation, Vol 12, Iss 12, Pp 2263-2266 (2021)

Abstract Diabetes is a rare, but potentially life‐threatening, adverse event of immune checkpoint inhibitors that requires prompt recognition and treatment. It usually occurs in the first 3 months of treatment and is typically related to programmed

Externí odkaz: https://doaj.org/article/2a1aeb43a15940f598a6167e5369bb97

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Autor: James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul D. Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey Weber

Publikováno v: Clinical Cancer Research. :OF1-OF10

Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::434061b974def7d4b67a0e16b85e1b6e
https://doi.org/10.1158/1078-0432.ccr-22-3145

Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Autor: Jeffrey Weber, Paolo A. Ascierto, Sonia Dolfi, Hao Tang, Margarita Askelson, Maurice Lobo, Corey Ritchings, Paola Queirolo, Nikhil I. Khushalani, Paul D. Nathan, Michael Millward, Leslie A. Fecher, Andrew G. Hill, Victoria Atkinson, Petr Arenberger, Luis de la Cruz-Merino, Jose Lutzky, Mark R. Middleton, Anna Maria Di Giacomo, Marcus O. Butler, Ivan Marquez-Rodas, Vanna Chiarion-Sileni, Jean-Jacques Grob, Michael Schenker, Charles Lance Cowey, Stéphane Dalle, Ana M. Arance Fernandez, Helen Gogas, Mario Mandalá, Michele Del Vecchio, James Larkin

DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52cb1057ddae601989ec0e00460b71a9
https://doi.org/10.1158/1078-0432.22787545.v1

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

Autor: Inês Pires da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John J. Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L. Smith, Richard A. Scolyer, Ana M. Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne N. Lo, Alexander M. Menzies

Publikováno v: Pires da Silva, I, Ahmed, T, McQuade, J L, Nebhan, C A, Park, J J, Versluis, J M, Serra-Bellver, P, Khan, Y, Slattery, T, Oberoi, H K, Ugurel, S, Haydu, L E, Herbst, R, Utikal, J, Pföhler, C, Terheyden, P, Weichenthal, M, Gutzmer, R, Mohr, P, Rai, R, Smith, J L, Scolyer, R A, Arance, A M, Pickering, L, Larkin, J, Lorigan, P, Blank, C U, Schadendorf, D, Davies, M A, Carlino, M S, Johnson, D B, Long, G V, Lo, S N & Menzies, A M 2022, ' Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 10, pp. 1068-1080 . https://doi.org/10.1200/JCO.21.01701

PURPOSE Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival to anti-programmed cell death protein 1 (anti–PD-1) monothera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76065c510604a83b0805fd88f0ad2d7
https://doi.org/10.1200/jco.21.01701

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Autor: James Larkin, Jeffrey Weber, Michele Del Vecchio, Helen Gogas, Ana M. Arance, Stephane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Iván Márquez-Rodas, Marcus O. Butler, Anna Marie Di Giacomo, Mark R. Middleton, Luis De la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Georgina V. Long, Maurice Lobo, Margarita Askelson, Paolo A. Ascierto, Mario Mandalá

Publikováno v: European journal of cancer (Oxford, England : 1990). 173

Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e960faf6450756b6ecff5831582d197
https://pubmed.ncbi.nlm.nih.gov/35964471